slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 47,761-47,790
Pages 3,679
Rows per page 30
Component
47,761-47,790 of 110,355
267
The slide uses a combination of summary text and direct interview transcripts to build a case of corporate misconduct.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
268
The slide presents a narrative of professional misconduct and coercion within an organ procurement organization.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
270
The slide uses anecdotal evidence from a 'prominent surgeon' to support a bearish thesis on TransMedics.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
271
The slide uses direct quotes from surgeons to build a narrative of financial unviability and institutional pushback against the product.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
272
The slide uses a Q&A format to directly contradict claims made by the TransMedics CEO regarding reimbursement pass-through.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
273
The slide uses direct quotes to build a narrative of customer churn and institutional resistance.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
274
The slide uses Q&A transcripts to highlight a shift away from OCS technology in high-volume transplant centers.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
275
The slide uses a 'villain critique' style to highlight negative sentiment from industry insiders regarding TransMedics.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
276
The slide uses a Q&A format to highlight a specific expert's negative sentiment toward TransMedics.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
277
The slide uses direct quotes from a high-volume TransMedics user to illustrate market vulnerability and the shift toward competitors offering more autonomy.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
278
The slide uses a Q&A format to build a narrative of market abandonment.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
279
The slide uses direct quotes from an UCSF administrator to build a case against TransMedics' long-term viability at the institution.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
280
The slide uses highlighted text to emphasize key negative sentiment regarding TransMedics' sustainability and market position.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
282
The slide uses a testimonial from a transplant surgeon to support a bearish thesis on the company's market position.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
283
The slide uses direct quotes from KOLs to frame the company's technology as a commoditized, overpriced solution with no clinical advantage over traditional cold storage.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
284
The slide uses direct quotes from a KOL to undermine the company's market position.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
285
The slide uses a 'villain critique' approach by aggregating expert opinions to undermine the company's value proposition.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
286
The slide uses a Q&A format to highlight the gap between the device's intended utility and real-world clinical experience.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
287
The slide uses highlighted text to emphasize key negative findings regarding the OCS technology's performance metrics.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
288
The slide uses a 'before-after' style comparison between a conceptual timeline and actual competitor hardware.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
289
The slide uses expert quotes to undermine the competitive moat of TransMedics by comparing it to existing, commoditized kidney perfusion technology.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
290
The slide uses a Q&A format to highlight the perceived lack of value proposition for the OCS Lung product.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
291
The slide uses direct quotes from a surgeon to undermine the company's value proposition.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
292
The slide uses highlighted text to emphasize key negative claims from a surgeon.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
293
The slide uses expert testimonials to argue that the TransMedics device is 'fatally flawed' because it does not allow for functional assessment under load.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
294
The slide uses direct quotes from surgeons to validate the market share shift thesis.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
295
The slide uses a direct quote from a surgeon to undermine the credibility and clinical utility of the TransMedics OCS device.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
296
The slide uses a direct quote from an expert to undermine the value proposition of the TransMedics device.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
297
The slide uses a quote-heavy structure to undermine the investment thesis for TransMedics (TMDX).TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
298
The slide uses a Q&A transcript format to highlight negative expert sentiment.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit